Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
David Baltimore Insider Profile
4 Followers
David Baltimore, Director at Amgen, holds 0.00 shares in Immune Design (Ticker: IMDZ), holds 44.13K shares in Regulus (Ticker: RGLS), holds 32.29K shares in Amgen (Ticker: AMGN).
Profitable Transactions
1 out of 6 Profitable Transactions
Average Return
-19.00%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Most Profitable Insider Trade
The most profitable trade made by David Baltimore
David Baltimore's Trading History
Amgen
May 01, 2018
Director
Uninformative Buy
―
$7.26M
Immune Design
Apr 04, 2019
―
Uninformative Sell
457.98K
$0.00
Regulus
Nov 13, 2018
Director
Uninformative Buy
―
$28.07K
List of latest transactions for each holding click on a transaction to see David Baltimore's performance on stock
You May Also Like
David Baltimore insider profile FAQ
What is the percentage of profitable transactions made by David Baltimore?
The percentage of profitable transactions made by David Baltimore is 17%.
What is the average return per transaction made by David Baltimore?
The average return per transaction made by David Baltimore is -19.00%.
What stocks does David Baltimore hold?
David Baltimore holds: AMGN, IMDZ, RGLS stocks.
What was David Baltimore’s latest transaction?
David Baltimore latest transaction was an Uninformative Sell of $457.98K.
What was David Baltimore's most profitable transaction?
David Baltimore’s most profitable transaction was an Informative Sell of AMGN stock on March 3, 2015. The return on the trade was 6.00%.
What is David Baltimore's role in Amgen?
David Baltimore's role in Amgen is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.